NeoGenomics (NEO) | Stock Overview & Key Data
NeoGenomics Performance Comparison
Stock Range
Today's Range
Low: $7.91
High: $8.38
on September 12, 2025
52 Week Range
Low: $4.72
High: $19.11
on August 1, 2025
on January 8, 2025
All-Time High: $61.57 on February 15, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.0B
EPS
-0.82
P/E Ratio (TTM)
-12.84
Forward P/E
39.80
P/B Ratio
1.20
PEG Ratio
-0.10
Div. Yield
N/A
ROE
-11.76%
Beta
1.615
Debt to Equity
48.21
Financial Highlights
Profitability
Gross Margin
42.61%
Operating Margin
-15.43%
Profit Margin
-15.10%
Returns and Earnings
Return on Assets (TTM)
-3.25%
Return on Equity (TTM)
-11.76%
EBITDA
$5.1M
Net Income (TTM)
$-104.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$5.38
Quarterly Revenue Growth (YoY)
10.20%
Quarterly Earnings Growth (YoY)
10.23%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| NeoGenomics NEO | 1.03B Small-cap | -0.25% | 30.92% | 7.71% | -22.19% | -51.73% | -51.46% | -20.16% | -77.78% |
| Thermo Fisher TMO | 181.05B Large-cap | -2.67% | 0.43% | 15.44% | -6.47% | -8.25% | -21.55% | -11.42% | 11.75% |
| Danaher DHR | 136.09B Large-cap | -5.07% | -7.62% | -7.34% | -7.27% | -17.30% | -30.70% | -22.62% | 3.91% |
| Twist Bioscience TWST | 1.53B Small-cap | -1.75% | -7.80% | -24.74% | -35.63% | -44.14% | -46.09% | -32.65% | -62.68% |
| Grail GRAL | 1.37B Small-cap | 3.06% | 13.21% | -9.26% | 23.31% | 112.28% | 169.98% | 160.19% | 160.19% |
| Neogen NEOG | 1.19B Small-cap | -4.35% | 5.16% | -2.14% | -41.98% | -53.94% | -65.90% | -65.86% | -85.42% |
Ownership & Short Interest
Insider Ownership
1.29%
Institutional Ownership
100.33%
Shares Short
5M
Short Ratio
1.67
Short % of Shares Outstanding
5.58%
Average 10-Day Volume
4M
Average 90-Day Volume
3M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is NEO's 52-week high and low?
- In the last 52 weeks, NeoGenomics reached a high of $19.11 (on January 8, 2025) and a low of $4.72 (on August 1, 2025).
- What is the market cap and P/E ratio for NEO?
- Curious about NeoGenomics's size and valuation? Its market capitalization stands at 1.03B. When it comes to valuation, the P/E ratio (trailing twelve months) is -12.84, and the forward P/E (looking ahead) is 39.80.
- Does NEO pay dividends? If so, what's the yield?
- As for dividends, NeoGenomics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are NeoGenomics's main competitors or similar companies to consider before investing?
When looking at NeoGenomics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Thermo Fisher
TMO181.05B Healthcare Diagnostics & Research -21.55% -11.42% Danaher
DHR136.09B Healthcare Diagnostics & Research -30.70% -22.62% Twist Bioscience
TWST1.53B Healthcare Diagnostics & Research -46.09% -32.65% Grail
GRAL1.37B Healthcare Diagnostics & Research 169.98% 160.19% Neogen
NEOG1.19B Healthcare Diagnostics & Research -65.90% -65.86% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for NeoGenomics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of NeoGenomics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -11.76%, the Debt to Equity ratio from the most recent quarter is 48.21, and its Gross Profit Margin stands at 42.61%.
- What is the recent revenue and earnings growth for NEO?
- Looking at NeoGenomics's growth, its revenue over the trailing twelve months (TTM) was $689M. Compared to the same quarter last year (YoY), quarterly revenue grew by 10.20%, and quarterly earnings saw a YoY growth of 10.23%.
- How much of NEO stock is held by insiders and institutions?
- Wondering who owns NeoGenomics stock? Company insiders (like executives and directors) hold about 1.29% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 100.33%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.